Read the Conversation
EF: Returning home as country President, how has Brazil received you, and what is your main mission in this new role?
AS: As the first female and entirely Brazilian president for Boehringer Ingelheim (BI) Brazil, I received a warm welcome. The supportive comments made me very happy, and the opportunity is incredibly exciting.
Returning to my homeland to impact the lives of millions of Brazilians positively resonates deeply with my purpose. Even though managing 1600 employees and their families is a significant responsibility, and working with the government to improve healthcare and bring innovations to patients is challenging, my task is inspiring. I step into this role, seeing this country’s potential for improvement and innovation.
EF: What is your strategy to gain new market share, and how are you planning to expand your access in your new pipeline segments?
AS: We have a lot of work ahead, continuing our ongoing projects. Last year, according to our internal data, we positively impacted around 1.5 million Brazilians with our human pharma innovative medicines and nearly 150 million animals with our animal health initiatives, according to our internal data. We have been experiencing double-digit growth, outpacing the human pharma and animal health market. However, abundant opportunities exist to expand our projects and enhance patient access.
We are gearing up to enter unfamiliar territories, especially with our remarkable products in the pipeline for oncology, mental health, cardio-renal-metabolic areas, and immunology. This involves shaping the market, reducing stigma, and ensuring patients receive the best care possible.
Creating a more sustainable healthcare system remains a universal challenge. Even getting a diagnosis is often a tough journey, particularly in rare diseases like generalized pustular psoriasis (GPP). Patients often suffer for years before diagnosis, and effective treatments can be hard to find. We are pioneering treatments in many of these areas to improve patient outcomes. There is groundwork to be done, but we have already taken crucial initial steps.
EF: What are the central pillars necessary for constructing a sustainable healthcare system in Brazil?
AS: To improve the healthcare system, one crucial aspect is partnering with the government to expedite patient access to health in general. For instance, Boehringer Ingelheim initiated a project called Abraçar, focusing on "business beyond the pill" experiences by collaborating with municipalities and states. An example is our effort to reduce diagnosis wait times for respiratory conditions like COPD. Patients previously waited over two years for a diagnosis due to long lines for spirometry tests. We supported approximately 50,000 tests in collaboration with cities, states, and hospitals, shortening the diagnosis time from two years to 5-6 months. This significantly benefits patients by allowing them to take an active role in managing their health.
Another key initiative involves the Health Economic-Industrial Complex, aligning with the government's goal of producing 70% of medications used in the public system. We announced a partnership with Fiocruz to support this objective and are collaborating in the manufacturing of a drug for Parkinson's disease. Since 75% of Brazil's population relies solely on the public system, partnerships like these are vital, as they contribute to the long-term sustainability of healthcare systems. With an aging population and rising chronic diseases, Boehringer Ingelheim is committed to collaboration and playing its part in improving the system, not only in Brazil but globally.
Another example of our commitment is our initiative to address adequate treatment of acute strokes through medical education and training of multidisciplinary teams. Stroke remains a leading cause of death and disability, preventing many patients from returning to work or functioning normally. We launched a global initiative in 2017 named ANGELS, and since then, more than 500 hospitals in Brazil have been trained on how to properly manage acute stroke patients. It is imperative to have hospitals prepared to recognize and treat stroke quickly because the first four hours are crucial for achieving a better outcome. We continue to work closely with these hospitals, increasing our reach each year and helping them with international quality certifications in stroke management.
These partnerships have a significant ripple effect. Patients benefit from better treatments that improve their outcomes. Consequently, as more patients return to work, they contribute and boost the economy. Helping thousands of patients positively impacts Brazil's healthcare system and society.
EF: What lessons can companies learn from Boehringer Ingelheim regarding addressing health threats at the human-animal-environment interface using the one health approach?
AS: The connection between humans and animals is strengthening, and it is a significant focus for us, given that Boehringer Ingelheim I is currently the second largest animal health company globally (considering our competitor's released statements versus our results). Our animal health business in Brazil is massive, covering pets, large animals, swine, and chickens. Brazil ranks high in this domain and is the second market at the Animal Health business in the world, owing to a growing population and changing how pets are perceived. We recently had an event at our BI office in Sao Paulo, where we brought together 40 veterinarians and experts to debate "One Health." During the event, we discussed the transmission of zoonotic diseases between pets and humans. Considering the conditions that can affect our pets and families, this is a crucial conversation to have. We are proud of our leading product, NexGard, a global blockbuster in pet health produced in Brazil. Our factory in Paulínia manufactures over 90% of NexGard for international use, benefiting the Brazilian economy and contributing to global export.
In animal health, prevention is vital. We offer a comprehensive portfolio of vaccines and products to tackle internal and external parasites. Viruses like rabies, which have reemerged in Brazil, emphasize the importance of prevention. Our interconnectedness with animals impacts both our physical and mental health. Mental health issues have risen during and after COVID, highlighting how our bond with pets can help alleviate these concerns.
However, our role extends beyond pets into large livestock animals. Brazil is a significant meat exporter and our products aid in reducing antibiotic usage and promoting sustainable health practices. This benefits the industry and the economy by preventing diseases that can substantially impact society.
EF: Based on your international experience, what fundamental principles are necessary to lead teams successfully?
AS: BI has been recognized as a top employer and a great workplace for seven consecutive years. We have fostered a positive and healthy environment that empowers and inspires our team and attracts new talent. Despite the vast cultural differences between countries like Brazil, Germany, Sweden, and Canada, the strong values of BI remain consistent. Respect, collaboration, and value for people are our most critical resources. Our unity comes from our shared purpose: to transform lives for generations.
Putting patients at the center of everything we do, whether they have two legs or four, motivates us. It transcends internal and external competition, focusing on delivering our purpose. People from various areas, even those not directly connected to patients, are inspired by our commitment and are deeply engaged in working together to make a difference.
Many employees, like myself, have been with BI for a long time because we resonate with the culture. The opportunities for personal development are immense, and the learning never stops. In my 14 years at BI, I have worked at our headquarters, led BI Sweden and BI Canada, and now returned to Brazil.
Over the last five years, we have supported over 100 employee moves outside of Brazil, with many colleagues returning more developed with new experiences. Brazilians are scattered worldwide, sharing their expertise and learning from different markets. This global perspective and agility have contributed to our success.
EF: What advice do you have for other women who want to accomplish or attain a leadership role like yours?
AS: My first advice is to believe in yourself. Women often only apply for positions if they meet 95% of the requirements. Men take more risks and use them even if they only match 50% of the criteria. It is key to trust your abilities, be bold, and apply for roles you are not 100% prepared for.
Secondly, networking is crucial. Women are great at networking for tasks but sometimes hesitate to promote their achievements. It is important to showcase your accomplishments and strategically advance in areas you want to develop. Connect with people who can help you reach your goals. These two tips can make a significant difference in your career.
